NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that data on DA-1726, a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, was accepted for one ePoster theater discussion and two general poster presentations at the American Diabetes Association 83rd Scientific Sessions, being held June 23-26, 2023 at the San Diego Convention Center in San Diego, CA and virtually.
“Having two posters selected, including one for an ePoster theater discussion, at such a prestigious scientific meeting, is a testament to the scientific community’s view of the strength of the preclinical data generated, thus far, for DA-1726,” stated Joe Hooker, Interim President and Chief Executive Officer of NeuroBo. “As previously announced, we intend to advance DA-1726, a long acting OXM analog that binds and activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors, leading to weight loss through reduced appetite and increased energy expenditure, through the IND process during the second half of this year. If accepted by the U.S. Food and Drug Administration, we plan to initiate a phase 1a safety study in the first half of 2024, with a data readout expected in the second half of 2024.”
ePoster Theater Presentation:
Yuna Chae, DA-1726 Project Manager, Dong-A ST Research Center, will present a digital poster and high-level overview of the poster findings in an open discussion with a session moderator.
Abstract Title: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
Presenter: Yuna Chae, DA-1726 Project Manager, Dong-A ST Research Center
Session: ePoster Theater
Date and Time: Sunday, June 25, 2023, 12:10 PM – 12:20 PM PDT
Location: Exhibit Hall (ePoster Theater A)
Poster: 1668
Poster Presentations:
Abstract Title: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
Authors: Tae-Hyoung Kim, Il-Hun Jung, Kyumin Kim, Hyung Heon Kim, Mi-Kyung Kim, Yuna Chae
Presenter: Tae-hyoung Kim, Dong-A ST Research Center
Session: General Poster Session
Date and Time: Monday, June 26, 2023, 11:30 AM – 12:30 PM PDT
Location: Poster Halls B-C
Poster: 1676
Abstract Title: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
Authors: Il-Hun Jung, Tae-Hyoung Kim, Su Jin Lee, Hyung Heon Kim, Mi-Kyung Kim, Yuna Chae
Presenter: Yuna Chae, Dong-A ST Research Center
Session: General Poster Session
Date and Time: Monday, June 26, 2023, 11:30 AM – 12:30 PM PDT
Location: Poster Halls B-C
Poster: 1668
Copies of abstracts will also be available on the NeuroBo Pharmaceuticals website at https://www.neurobopharma.com/presentations following completion of the live presentation.
